Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: john.d who wrote (7481)	7/4/2001 3:06:07 PM
From: john.d	Read Replies (2) \| Respond to of 14101

Here's the part of the announcement that is very disappointing. The EU mutual recognition did not officially commence until today. Just lovely. Doesn't appear to be a Dimethaid initiated delay but disappointing none the less. John Separately, Dimethaid has been informed by the United Kingdom Medicines Control Agency, the Company's Reference Member State (RMS), that because of dossier processing delays by the Concerned Member States (CMS), the 60-day review period of the EU Mutual Recognition Procedure (MRP) officially commenced on July 4, 2001. According to the MRP regulations, this review period should have begun shortly after the filing of the UK's Assessment Report on May 9, 2001. As a result, decisions from the 13 CMS are expected to be forthcoming by the end of summer. The delay in EU approvals has no bearing on the Company's negotiations with potential distribution partner(s) in the CMS and the Company continues to work towards their completion prior to further EU approvals.